Labcorp Holdings Inc. LH
- Market cap
- $21.9B
- P/E
- 25.4×
Follow LH
Labcorp Holdings Inc. (LH) Free cash flow
Labcorp Holdings Inc.'s free cash flow for fiscal 2025 was $1.2B, up 10.6% from $1.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $727.2M (fiscal 2015) to $2.8B (fiscal 2021); the current reading is higher than 73% of that period. Labcorp Holdings Inc. ranks 7th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.2B | 10.57% |
| FY2024 | $1.1B | 25.52% |
| FY2023 | $874.7M | (42.76%) |
| FY2022 | $1.5B | (44.94%) |
| FY2021 | $2.8B | 54.56% |
| FY2020 | $1.8B | 70.66% |
| FY2019 | $1.1B | 7.84% |
| FY2018 | $975.7M | (17.88%) |
| FY2017 | $1.2B | 25.21% |
| FY2016 | $949.0M | 30.50% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $315.8M | 303.32% |
| Mar 2026 | $78.3M | (84.18%) |
| Dec 2025 | $494.8M | 75.71% |
| Sep 2025 | $281.6M | (48.29%) |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.3B |
| LH Labcorp Holdings Inc. | $1.2B |
| ICLR ICON PLC compare | $883.8M |
| MTD Mettler-Toledo International, Inc. compare | $864.0M |
| MEDP Medpace Holdings, Inc. compare | $706.7M |
| RVTY Revvity Inc. compare | $570.2M |
| CRL Charles River Laboratories International, Inc. compare | $370.6M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on LH
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement